Showing 1961-1970 of 2123 results for "".
- FDA Clears IND Application of Gene Therapy for Tay-Sachs and Sandhoff Diseaseshttps://practicalneurology.com/news/fda-clears-ind-application-of-gene-therapy-for-tay-sachs-and-sandhoff-diseases/2469420/The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a registrational study of adeno-associated viral (AAV) vector gene therapy (AXO-AAV-GM2; Axovant Gene Therapies, New York, NY) to treat individuals with Tay-Sachs disease and Sandhoff dis
- Society of Vascular and Interventional Neurology Launches Stroke Awareness Campaignhttps://practicalneurology.com/news/society-of-vascular-and-interventional-neurology-launches-stroke-awareness-campaign/2469413/The Society of Vascular and Interventional Neurology (SVIN) global campaign, Mission Thrombectomy 2020 (MT2020) has published a white paper, Mechanical Thrombectomy for Acute Stroke. Building Thrombectomy Systems of Care in Your Region: Why and How. The white paper is targeted towards health poli
- FDA Clears Trigeminal Nerve Stimulator Migraine Treatment for Use Without Prescriptionhttps://practicalneurology.com/news/fda-clears-trigeminal-nerve-stimulator-migraine-treatment-for-use-without-prescription/2469399/The Food and Drug Administration (FDA) has cleared the external trigeminal nerve stimulator (Cefaly Dual; Cefaly Technology, New York, NY ) for the acute and preventative migraine treatment in individuals age 18 years or more without a prescription. Initial purchase of the device
- Gene Therapy Improves ON Time for Individuals With Parkinson Disease in Phase 3 Trialhttps://practicalneurology.com/news/gene-therapy-improves-on-time-for-individuals-with-parkinson-disease-in-phase-3-trial/2469394/The 6-month follow-up data of a phase 2 study of a .4 x 107 TU dose of gene therapy (AXO-Lenti-PD; Axovant Gene Therapies, New York, NY) for Parkinson disease (PD) treatment showed the gene therapy improved ON time by more than 2-hours. The therapy is delivered to the putamin in a neurosurgi
- Soticlestat in Rare Epilepsies CDKL5 Deficiency and Dup15q Syndrome Phase 2 Clinical Trialshttps://practicalneurology.com/news/soticlestat-in-rare-epilepsies-cdkl5-deficiency-and-dup15q-syndrome-phase-2-clinical-trials/2469390/In the ARCADE (NCT03694275) and ENDYMION (NCT03635073) studies of soticlestat (OV935/TAK-935, Ovid Therapeutics, New York, NY) seizure frequency in individuals with CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) decreased. The combined data from ARCADE and ENDYMION studies
- Risdiplam Improves Motor Function in Infants with Type 1 SMAhttps://practicalneurology.com/news/risdiplam-improves-motor-function-in-infants-with-type-1-sma/2469388/In the 2-year pivotal FIREFISH study (NCT02913482) of risdiplam (Evrysdi; Genentech, San Francisco, CA), infants with symptomatic type 1 spinal muscular atrophy (SMA) who were treated with risdiplam at age 2 to 7 months continued to improve and achieve motor milestones. Of the 21 partic
- Biomarkers May Predict Who May Need More Time to Recover From Concussionhttps://practicalneurology.com/news/biomarkers-may-predict-who-may-need-more-time-to-recover-from-concussion/2469365/A research study published in JAMA Network open identified blood biomarkers that could help to predict need for additional time to recover from a sports-related concussion. Using an ultrasensitive assay that can detect minute amounts of protein in serum, researchers found that tau
- Virtual Programs and Events Available to Support PD Community Through Ongoing COVID-19 Pandemichttps://practicalneurology.com/news/virtual-programs-and-events-available-to-support-pd-community-through-ongoing-covid-19-pandemic/2469361/The Parkinson's Foundation has continued to host virtual programs and events to support the Parkinson disease (PD) community during the ongoing COVID-19 pandemic. This year, their signature event Fall Moving Day will be online. The Foundation has new events prepared for PD Health@Home, a virt
- Soticlestat Reduces Seizure Frequency in Children with Dravet or Lennox-Gastaut Syndromehttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-children-with-dravet-or-lennox-gastaut-syndrome/2469360/Data from a randomized phase 2 ELEKTRA study (NCT03650452) (Takeda Pharmaceutical, New York, NY) showed soticlestat treatment reduced seizure frequency in children with Dravet syndrome (DS) or Len
- FDA Gives Green Light to Trehelose Phase 2b/3 Trial for ALShttps://practicalneurology.com/news/fda-gives-green-light-to-trehelose-phase-2b3-trial-for-als/2469350/The Food and Drug Administration (FDA) has issued a may proceed notice, allowing the initiation of a phase 2b/3 trial studying trehalose (SLS-005, Seelos Therapeutics, New York, NY) for the treatment of amyotrophic lateral sclerosis (ALS). Familial ALS is caused by mutations in th